Advanced NanoTherapies
Drug-coated balloons engineered to deliver stent-like patency and restenosis prevention with long-term release of synergistic drugs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $4.0m Valuation: $36.0m | Series A |
| Total Funding | 000k | ||
Related Content
Advanced NanoTherapies, Inc. is a pioneering company in the medical technology sector, specializing in nanoparticle drug delivery systems. The company focuses on developing advanced therapeutic solutions for coronary artery disease (CAD) and peripheral artery disease (PAD). Their flagship product, SirPlux Duo DCB, is engineered to deliver two synergistic drugs, Sirolimus and Paclitaxel, simultaneously. This innovative approach aims to inhibit cell growth at a higher potency and lower dosage compared to existing treatments, offering a next-generation front-line therapy for cardiovascular conditions.
The company operates primarily in the healthcare and medical technology markets, targeting hospitals, clinics, and medical professionals specializing in cardiovascular treatments. Their business model revolves around the development and eventual commercialization of their proprietary drug delivery platforms. Although their products are currently in the development phase and not yet available for sale, the company plans to generate revenue through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.
Advanced NanoTherapies leverages its A.N.T. nanoparticle platform to provide sustained drug release and retention in tissue, resulting in stent-like patency and improved restenosis prevention. The platform is drug-agnostic, meaning it can be adapted for use with various drug combinations, making it versatile for multiple medical applications beyond cardiovascular treatments, including neurology, ENT, and orthopedics.
Keywords: nanoparticle, drug delivery, coronary artery disease, peripheral artery disease, Sirolimus, Paclitaxel, cardiovascular, medical technology, sustained release, restenosis prevention.